TWI686406B - 結合ｔｉｍ-３之抗體分子及其用途 - Google Patents

結合ｔｉｍ-３之抗體分子及其用途 Download PDF

Info

Publication number
TWI686406B
TWI686406B TW104103319A TW104103319A TWI686406B TW I686406 B TWI686406 B TW I686406B TW 104103319 A TW104103319 A TW 104103319A TW 104103319 A TW104103319 A TW 104103319A TW I686406 B TWI686406 B TW I686406B
Authority
TW
Taiwan
Prior art keywords
amino acid
acid sequence
sequence seq
tim
seq
Prior art date
Application number
TW104103319A
Other languages
English (en)
Chinese (zh)
Other versions
TW201612193A (en
Inventor
巴芭拉 巴妮緹
艾倫Ｓ 哈利斯
湯瑪斯 胡伯
湯瑪士 沛卓卡
珍妮佛 瑪麗 瑪塔拉薩
佩頓 凱薩琳 安妮 薩巴透斯
華特Ａ 布萊特兒
丹尼爾Ｊ 希克林
梅西米里諾 法斯庫斯
蘿絲瑪麗Ｈ 迪克洛菲
戴爾Ｔ 悠魅蘇
高登 詹姆士 費里曼
胡天岑
約翰Ａ 塔拉斯加
許方敏
Original Assignee
美商達納 法伯癌症協會
美商兒童醫療中心公司
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52478098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI686406(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商達納 法伯癌症協會, 美商兒童醫療中心公司, 瑞士商諾華公司 filed Critical 美商達納 法伯癌症協會
Publication of TW201612193A publication Critical patent/TW201612193A/zh
Application granted granted Critical
Publication of TWI686406B publication Critical patent/TWI686406B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G01N33/5759—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
TW104103319A 2014-01-31 2015-01-30 結合ｔｉｍ-３之抗體分子及其用途 TWI686406B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461934469P 2014-01-31 2014-01-31
US61/934,469 2014-01-31
US201462094912P 2014-12-19 2014-12-19
US62/094,912 2014-12-19

Publications (2)

Publication Number Publication Date
TW201612193A TW201612193A (en) 2016-04-01
TWI686406B true TWI686406B (zh) 2020-03-01

Family

ID=52478098

Family Applications (2)

Application Number Title Priority Date Filing Date
TW104103319A TWI686406B (zh) 2014-01-31 2015-01-30 結合ｔｉｍ-３之抗體分子及其用途
TW109103123A TWI769434B (zh) 2014-01-31 2015-01-30 結合ｔｉｍ-３之抗體分子及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109103123A TWI769434B (zh) 2014-01-31 2015-01-30 結合ｔｉｍ-３之抗體分子及其用途

Country Status (34)

Country Link
US (6) US9605070B2 (enExample)
EP (3) EP4324518A3 (enExample)
JP (3) JP6539667B2 (enExample)
KR (2) KR20220028145A (enExample)
CN (2) CN113896791A (enExample)
AU (2) AU2015210750B2 (enExample)
CA (1) CA2936863A1 (enExample)
CL (1) CL2016001716A1 (enExample)
CR (1) CR20160347A (enExample)
CU (1) CU24427B1 (enExample)
CY (1) CY1121893T1 (enExample)
DK (1) DK3099717T3 (enExample)
EA (1) EA201691556A1 (enExample)
EC (1) ECSP16070447A (enExample)
ES (2) ES2972425T3 (enExample)
HR (1) HRP20191083T1 (enExample)
HU (1) HUE045065T2 (enExample)
IL (1) IL246693B2 (enExample)
JO (2) JOP20200096A1 (enExample)
LT (1) LT3099717T (enExample)
ME (1) ME03489B (enExample)
MX (2) MX375953B (enExample)
MY (1) MY187296A (enExample)
NZ (2) NZ761188A (enExample)
PE (1) PE20170330A1 (enExample)
PH (1) PH12016501482B1 (enExample)
PL (1) PL3099717T3 (enExample)
PT (1) PT3099717T (enExample)
RS (1) RS59065B1 (enExample)
SG (1) SG11201605627TA (enExample)
SI (1) SI3099717T1 (enExample)
TW (2) TWI686406B (enExample)
UY (2) UY35973A (enExample)
WO (1) WO2015117002A1 (enExample)

Families Citing this family (351)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709412B2 (en) * 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
US8652465B2 (en) * 2005-06-08 2014-02-18 Emory University Methods and compositions for the treatment of persistent infections
EP3002296B1 (en) * 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla antibodies and uses thereof
PT2686347T (pt) 2011-03-16 2018-07-05 Argenx Bvba Anticorpos dirigidos contra cd70
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
KR20230097209A (ko) 2014-03-12 2023-06-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
EP4180041A1 (en) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
PL3183268T3 (pl) 2014-08-19 2020-09-07 Novartis Ag Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US20170281624A1 (en) 2014-09-13 2017-10-05 Novartis Ag Combination therapies of alk inhibitors
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3662903A3 (en) * 2014-10-03 2020-10-14 Novartis AG Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016057705A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
SG11201703403TA (en) * 2014-10-27 2017-05-30 Agency Science Tech & Res Anti-tim-3 antibodies
GB201419094D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
MX387463B (es) * 2014-11-20 2025-03-18 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas activadoras de células t y antagonistas de unión al eje de pd-1 y usos de los mismos para el tratamiento de cáncer.
RS60615B1 (sr) 2014-11-20 2020-08-31 Hoffmann La Roche Zajednički laki lanci i postupci upotrebe
CN107074955B (zh) 2014-11-20 2021-06-22 豪夫迈·罗氏有限公司 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
SG11201707800QA (en) 2015-03-23 2017-10-30 Bayer Pharma AG Anti-ceacam6 antibodies and uses thereof
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
US20180153986A1 (en) * 2015-04-24 2018-06-07 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
EP3298021B1 (en) 2015-05-18 2019-05-01 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs having increased bioavailability
US10316097B2 (en) * 2015-05-27 2019-06-11 Ucb Biopharma Sprl Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody
TWI859112B (zh) 2015-07-21 2024-10-21 瑞士商諾華公司 改良免疫細胞之功效及擴展之方法
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
JP6878405B2 (ja) 2015-07-29 2021-05-26 ノバルティス アーゲー Ｐｄ−１に対する抗体分子を含む組み合わせ治療
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3337826A1 (en) * 2015-08-20 2018-06-27 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
EP3356551B1 (en) 2015-09-29 2020-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of b-lymphomas
IL257110B (en) 2015-10-02 2022-09-01 Hoffmann La Roche Bispecific antibodies specific against pd1 and tim3
EP4046655A1 (en) * 2015-11-03 2022-08-24 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
JP6587756B2 (ja) * 2015-11-04 2019-10-09 デューク ユニバーシティー 免疫毒素およびチェックポイント阻害剤の併用療法
WO2017087547A1 (en) * 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
CN109069597A (zh) 2015-12-22 2018-12-21 诺华股份有限公司 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
EP3400443B1 (en) 2016-01-04 2020-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
EA039865B1 (ru) 2016-01-11 2022-03-22 Универзитет Цюрих Иммуностимулирующее гуманизированное моноклональное антитело против интерлейкина-2 человека и слитый белок
TW202409084A (zh) 2016-03-04 2024-03-01 美商Ｊｎ生物科學有限責任公司 針對tigit之抗體
EP3423482A1 (en) 2016-03-04 2019-01-09 Novartis AG Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
NZ746755A (en) 2016-04-12 2025-11-28 Servier Lab Anti-tim-3 antibodies and compositions
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR102366813B1 (ko) 2016-05-27 2022-02-24 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
CN107474136B (zh) * 2016-06-08 2023-03-07 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
CN109562102A (zh) 2016-06-17 2019-04-02 宾夕法尼亚大学董事会 用于预防和/或治疗癌症的化合物、组合物和方法
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
PE20190418A1 (es) * 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
WO2018014001A1 (en) 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
JP7158104B2 (ja) * 2016-07-15 2022-10-21 ビラクタ セラピューティクス，インク． Ｎｋ細胞ベースの療法で使用するためのｈｄａｃ阻害剤
US20210369746A1 (en) * 2016-08-01 2021-12-02 Molecular Templates, Inc. Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
TWI769174B (zh) * 2016-08-26 2022-07-01 英屬開曼群島商百濟神州有限公司 抗tim-3抗體及其用途
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
TWI764943B (zh) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
JP2019537438A (ja) * 2016-11-01 2019-12-26 アナプティスバイオ インコーポレイティッド Ｔｉｍ−３（ｔ細胞イムノグロブリンおよびムチンタンパク質３）に対する抗体
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN108101989A (zh) * 2016-11-24 2018-06-01 复旦大学 针对人tim-3的全人源单域抗体及应用
US11230596B2 (en) 2016-11-30 2022-01-25 Mereo Biopharma 5, Inc. Methods for treatment of cancer comprising TIGIT-binding agents
MX2019006285A (es) 2016-12-03 2019-12-16 Juno Therapeutics Inc Metodos para modulacion de celulas cart-t.
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
CN110023338A (zh) 2016-12-08 2019-07-16 伊莱利利公司 用于与抗pd-l1抗体组合的抗tim-3抗体
TWI665216B (zh) * 2016-12-29 2019-07-11 財團法人生物技術開發中心 抗人類tim-3抗體及其使用方法
CN108264557B (zh) * 2016-12-30 2021-08-24 惠和生物技术(上海)有限公司 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用
EP3565598A4 (en) * 2017-01-03 2020-10-28 Trellis Bioscience, LLC NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS
BR112019014169A2 (pt) * 2017-01-09 2020-02-11 Tesaro, Inc. Métodos de tratamento de câncer com anticorpos anti-tim-3
JP7280828B2 (ja) * 2017-01-23 2023-05-24 クレージュ メディカル カンパニー，リミテッド Ｂｃｍａを標的とする抗体およびその使用
JP7132230B2 (ja) 2017-02-10 2022-09-06 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｔｒａｉｌショート抗体及び使用方法
WO2018156785A1 (en) * 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
EP3587452A4 (en) * 2017-02-27 2021-03-03 Jiangsu Hengrui Medicine Co., Ltd. ANTI-TIM-3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF IT, AND MEDICAL USES OF IT
US11596629B2 (en) * 2017-02-28 2023-03-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
EP3592868B1 (en) 2017-03-06 2022-11-23 Novartis AG Methods of treatment of cancer with reduced ubb expression
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
EP3600427A1 (en) 2017-03-24 2020-02-05 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
EP3600282B1 (en) 2017-03-31 2025-09-10 Corcept Therapeutics Incorporated Glucocorticoid receptor modulators to treat cervical cancer
MY204068A (en) 2017-04-05 2024-08-06 Servier Lab Combination therapies targeting pd-1, tim-3, and lag-3
JOP20190222A1 (ar) * 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
CN108948193B (zh) * 2017-05-18 2022-12-09 上海健信生物医药科技有限公司 针对tim-3的抗体分子,抗原结合片段及其医药用途
CN111107868A (zh) 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
JP7791642B2 (ja) 2017-05-24 2025-12-24 ノバルティス アーゲー 抗体－サイトカイングラフト化タンパク質及び癌の治療における使用方法
WO2018218137A1 (en) 2017-05-25 2018-11-29 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
CA3065929A1 (en) 2017-06-01 2018-12-06 Michael Wayne SAVILLE Bispecific antibodies that bind cd123 and cd3
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
PE20200717A1 (es) 2017-06-22 2020-07-21 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
AU2018287519B2 (en) 2017-06-22 2021-07-22 Novartis Ag IL-1beta binding antibodies for use in treating cancer
AU2018292618A1 (en) * 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof
JP2020526194A (ja) 2017-06-29 2020-08-31 ジュノー セラピューティクス インコーポレイテッド 免疫療法薬と関連する毒性を評価するためのマウスモデル
KR20200031659A (ko) 2017-07-20 2020-03-24 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
EP3658141B1 (en) * 2017-07-24 2022-11-16 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Treating pathological conditions by direct and indirect targeting of sirpalpha - cd47 interaction
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
EP3658185A4 (en) * 2017-07-28 2021-07-14 Phanes Therapeutics, Inc. ANTI-TIM-3 ANTIBODIES AND USES THEREOF
IL310079A (en) * 2017-08-28 2024-03-01 Bristol Myers Squibb Co TIM-3 antagonists for the treatment and diagnosis of cancer
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
CN109554469B (zh) * 2017-09-26 2021-10-12 北京大学 T细胞急性淋巴性白血病的肿瘤细胞及其分子标志
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
AU2018358067A1 (en) 2017-11-01 2020-05-07 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
US20200353050A1 (en) 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
BR112020010148A2 (pt) 2017-11-29 2020-10-13 Taiho Pharmaceutical Co., Ltd. compostos de sulfonamida e uso dos mesmos
MX2020005651A (es) 2017-11-30 2020-10-28 Novartis Ag Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
CN109870581B (zh) * 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 一种定量检测HBsAg的试剂盒及方法
WO2019117659A1 (ko) * 2017-12-14 2019-06-20 엘지전자 주식회사 움직임 벡터 도출을 기반으로 하는 영상 코딩 방법 및 그 장치
WO2019118855A1 (en) * 2017-12-14 2019-06-20 The Trustees Of The University Of Pennsylvania Compounds and compositions for prevention and/or treatment of cancer
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
EP3735590A1 (en) 2018-01-04 2020-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
BR112020013672A2 (pt) 2018-01-05 2020-12-01 Cybrexa 1, Inc. compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
KR102813913B1 (ko) * 2018-01-12 2025-05-30 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2019143607A1 (en) 2018-01-16 2019-07-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
WO2019152743A1 (en) 2018-01-31 2019-08-08 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
EP3756012A1 (en) 2018-02-21 2020-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
JP7170737B2 (ja) 2018-02-27 2022-11-14 レイドス， インコーポレイテッド Ｐｄ－１ペプチド阻害剤
CN110272489B (zh) * 2018-03-15 2023-08-22 上海健信生物医药科技有限公司 一种针对tim-3的全人源化抗体分子, 抗原结合片段及其医药用途
CN110305216B (zh) * 2018-03-20 2022-09-02 无锡智康弘义生物科技有限公司 新型抗tim-3抗体
WO2019179420A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
EP3774834A1 (en) 2018-03-27 2021-02-17 Boehringer Ingelheim International GmbH Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists
US20210024567A1 (en) 2018-03-27 2021-01-28 Boehringer Ingelheim International Gmbh Modified cyclic dinucleotide compounds
CN111989341B (zh) 2018-04-12 2023-06-02 南京维立志博生物科技有限公司 结合tim-3的抗体及其用途
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
KR20210003170A (ko) 2018-04-18 2021-01-11 젠코어 인코포레이티드 IL-15/IL-15Rα 이종이량체 Fc 융합 단백질 및 이의 용도
JP7328324B2 (ja) * 2018-04-24 2023-08-16 アンプソース・バイオファーマ・シャンハイ・インコーポレイテッド Ｔｉｍ－３に対する抗体およびその使用
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3797123A4 (en) 2018-05-23 2022-03-02 BeiGene, Ltd. ANTI-OX40 ANTIBODIES AND METHODS OF USE
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
JP2021525769A (ja) 2018-06-01 2021-09-27 ノバルティス アーゲー Ｃｄ１２３及びｃｄ３に結合する二重特異性抗体の投与
CN112236416B (zh) 2018-06-04 2024-03-01 科赛普特治疗公司 嘧啶环己烯基糖皮质激素受体调节剂
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210347842A1 (en) 2018-06-19 2021-11-11 Eli Lilly And Company Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
CN111902428B (zh) * 2018-07-03 2023-11-10 上海健信生物医药科技有限公司 一种双特异性抗体及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR102873348B1 (ko) 2018-07-10 2025-10-20 노파르티스 아게 3-(5-하이드록시-1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 ikaros 패밀리 아연 핑거 2(ikzf2)-의존성 질환의 치료에 있어서의 이의 용도
TWI822815B (zh) * 2018-07-14 2023-11-21 財團法人生物技術開發中心 抗-人類ｐｄ-ｌ１之抗體及其用途
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
PE20210406A1 (es) 2018-07-25 2021-03-02 Novartis Ag Inhibidores de inflamasoma nlrp3
MX2021001516A (es) * 2018-08-20 2021-04-19 Jiangsu Hengrui Medicine Co Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores.
BR112021003018A2 (pt) 2018-08-21 2021-05-11 Albert Einstein College Of Medicine anticorpos monoclonais contra tim-3 humana
US20210261663A1 (en) 2018-08-28 2021-08-26 Jiangsu Hengrui Medicine Co., Ltd. Anti-tim3 antibody pharmaceutical composition and use thereof
AU2019328575B2 (en) 2018-08-30 2024-07-11 Immunitybio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
EP4659757A3 (en) 2018-08-30 2026-01-14 ImmunityBio, Inc. Multi-chain chimeric polypeptides and uses thereof
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN112739360A (zh) 2018-09-26 2021-04-30 安斯泰来制药株式会社 基于溶瘤性牛痘病毒与免疫检查点抑制剂的联用的癌症疗法以及其中使用的药物组合物和组合药物
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
PE20211055A1 (es) 2018-10-12 2021-06-07 Xencor Inc Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
EP3873611A1 (en) 2018-11-01 2021-09-08 Merck Patent GmbH Anti-tim-3 antibodies
TW202021981A (zh) 2018-11-01 2020-06-16 美商奇諾治療有限公司 G蛋白偶合受體c類第5群成員d（gprc5d）特異性嵌合抗原受體
AU2019372436A1 (en) * 2018-11-01 2021-05-20 Merck Patent Gmbh Methods of administering anti-TIM-3 antibodies
BR112021008289A2 (pt) 2018-11-01 2021-10-26 Juno Therapeutics, Inc. Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b
WO2020102721A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Immune monitoring of neuro-inflammatory amyotrophic lateral sclerosis (als)
JP2022513062A (ja) 2018-11-16 2022-02-07 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞悪性腫瘍を処置するために、操作されたｔ細胞を投薬する方法
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
WO2020104496A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
CN111253485A (zh) * 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 抗人tim-3单克隆抗体及其应用
CN113710256A (zh) 2018-11-30 2021-11-26 朱诺治疗学股份有限公司 使用过继细胞疗法的治疗方法
EP3890749B1 (en) 2018-12-04 2025-10-29 Sumitomo Pharma America, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
US20220064332A1 (en) 2018-12-19 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
WO2020126808A1 (en) 2018-12-19 2020-06-25 Bayer Aktiengesellschaft Pharmaceutical combination of anti ceacam6 and tim3 antibodies
WO2020128892A1 (en) 2018-12-20 2020-06-25 Novartis Ag Extended low dose regimens for mdm2 inhibitors
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
AU2019409139A1 (en) 2018-12-21 2021-06-03 Novartis Ag Use of IL-1β binding antibodies
US20200369762A1 (en) 2018-12-21 2020-11-26 Novartis Ag Use of il-1beta binding antibodies
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
PH12021551479A1 (en) 2018-12-21 2022-07-18 Novartis Ag Antibodies to pmel17 and conjugates thereof
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
MX2021009087A (es) 2019-01-29 2021-09-08 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
EP3918323A4 (en) * 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
WO2020157131A1 (en) 2019-01-30 2020-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
EP3919903B1 (en) * 2019-01-31 2025-01-08 Sekisui Medical Co., Ltd. Method for immunological analysis of free aim in biological sample, and measurement kit
WO2020161083A1 (en) 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
JP7662528B2 (ja) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
US20220098674A1 (en) 2019-02-13 2022-03-31 Inserm (Institut National De La Santé Et Dr La Recherch Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
JP7547360B2 (ja) 2019-03-22 2024-09-09 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
AU2020253955A1 (en) * 2019-04-03 2021-09-09 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
JP7650243B2 (ja) * 2019-04-26 2025-03-24 ユニバーシティー オブ ヒューストン システム 上皮組織の慢性炎症性傷害、化生、異形成、及びがんを治療するための方法ならびに組成物
EP3963109A1 (en) 2019-04-30 2022-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2020237050A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
TWI781405B (zh) * 2019-05-29 2022-10-21 日商大鵬藥品工業股份有限公司 使用磺醯胺化合物與免疫調節劑之癌併用療法
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
KR20220035394A (ko) 2019-06-21 2022-03-22 에이치씨더블유 바이올로직스, 인크. 다중-사슬 키메라 폴리펩티드 및 이의 용도
JP2022537411A (ja) * 2019-06-21 2022-08-25 シングル セル テクノロジー， インコーポレイテッド 抗ｔｉｍ－３抗体
KR20220028075A (ko) 2019-07-03 2022-03-08 스미토모 다이니폰 파마 온콜로지, 인크. 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
AU2020311925A1 (en) 2019-07-10 2022-02-03 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
BR112022000337A2 (pt) 2019-07-10 2022-04-12 Cybrexa 2 Inc Conjugados de peptídeos de citotoxinas como terapêuticos
CN110407938B (zh) * 2019-08-12 2020-03-06 北京昭衍生物技术有限公司 抗tim-3单克隆抗体、表达载体及其应用
JP2022547234A (ja) 2019-08-29 2022-11-10 アステラス製薬株式会社 遺伝子操作された腫瘍溶解性ワクシニアウイルスおよびその使用方法
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
JP2022548627A (ja) * 2019-09-16 2022-11-21 ノバルティス アーゲー 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4037714A1 (en) 2019-10-03 2022-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
WO2021067863A2 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CA3154280A1 (en) * 2019-10-11 2021-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting cd13 and tim-3 with car t cells to treat acute myeloid leukemia
MX2022004487A (es) 2019-10-16 2022-05-06 Corcept Therapeutics Inc Metodo para normalizar el indice de neutrofilos a linfocitos en pacientes con cancer con un antagonista del receptor de glucocorticoide selectivo.
EP4045686A1 (en) 2019-10-17 2022-08-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for diagnosing nasal intestinal type adenocarcinomas
WO2021079188A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
EP4048285A1 (en) 2019-10-21 2022-08-31 Novartis AG Tim-3 inhibitors and uses thereof
WO2021083959A1 (en) 2019-10-29 2021-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating uveal melanoma
MX2022006149A (es) * 2019-11-21 2022-06-17 Beigene Ltd Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tim3.
EP4076508A1 (en) 2019-12-19 2022-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions to treat cancers
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
JP2023509516A (ja) 2020-01-07 2023-03-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
MX2022008771A (es) 2020-01-14 2022-10-07 Synthekine Inc Metodos y composiciones de muteinas de il2 sesgadas.
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021144426A1 (en) 2020-01-17 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP4100126A1 (en) 2020-02-05 2022-12-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
IL295083A (en) 2020-02-11 2022-09-01 Hcw Biologics Inc Methods for activating regulatory t cells
EP4103600A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Chromatography resin and uses thereof
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
KR102572804B1 (ko) * 2020-02-25 2023-08-31 국립암센터 CD11b+ 세포에서 TIM-3의 발현 수준을 측정하는 암 진단 또는 예후 예측을 위한 정보제공 방법
US20230113705A1 (en) 2020-02-28 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
WO2021171264A1 (en) 2020-02-28 2021-09-02 Novartis Ag Dosing of a bispecific antibody that binds cd123 and cd3
WO2021207689A2 (en) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
WO2021209356A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
AU2021262794A1 (en) 2020-04-29 2022-11-24 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
WO2021252099A2 (en) * 2020-05-04 2021-12-16 Virginia Commonwealth University Antimicrobial and antitoxin compositions and methods for treatment
WO2021231908A2 (en) * 2020-05-15 2021-11-18 Fred Hutchinson Cancer Research Center Compositions and methods for enhancing cancer immunotherapy
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
WO2021247604A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
KR20230019152A (ko) 2020-06-02 2023-02-07 아르커스 바이오사이언시즈 인코포레이티드 Tigit에 대한 항체
WO2021247789A1 (en) 2020-06-04 2021-12-09 Leidos, Inc. Immunomodulatory compounds
CN116813777A (zh) 2020-06-22 2023-09-29 恩格姆生物制药公司 Lair-1结合剂及其使用方法
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
US20230266332A1 (en) 2020-07-28 2023-08-24 Inserm (Institut National De La Santè Et De La Recherch Médicale) Methods and compositions for preventing and treating a cancer
JP2023536466A (ja) 2020-07-31 2023-08-25 レイドス， インコーポレイテッド Ｌａｇ３結合ペプチド
CN116134027B (zh) 2020-08-03 2025-01-24 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
WO2022081426A1 (en) 2020-10-12 2022-04-21 Leidos, Inc. Immunomodulatory peptides
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
WO2022101481A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
EP4244392A1 (en) 2020-11-16 2023-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for predicting and treating uveal melanoma
WO2022106579A1 (en) * 2020-11-20 2022-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for treating a disease associated with macrophage senescence
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
CA3204162A1 (en) 2021-01-11 2022-07-14 Robert Kastelein Compositions and methods related to receptor pairing
AU2022212123A1 (en) 2021-01-29 2023-09-07 Board Of Regents, The University Of Texas System Methods of treating cancer with kinase inhibitors
WO2022194908A1 (en) 2021-03-17 2022-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4319755A4 (en) 2021-04-08 2025-03-26 Board of Regents, The University of Texas System Compounds and methods for theranostic targeting of parp activity
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
MX2023012277A (es) 2021-04-16 2023-12-07 Novartis Ag Conjugados anticuerpo-fármaco y métodos para fabricar los mismos.
JP2024516616A (ja) * 2021-04-23 2024-04-16 スゾウ ネオロジクス バイオサイエンス シーオー．， エルティーディー． Ｔｉｍ－３を標的とする抗体及びその使用
EP4326903A1 (en) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating cell senescence accumulation related disease
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4370139A4 (en) 2021-07-14 2025-10-15 Synthekine Inc METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY FOR NEOPLASTIC DISEASE
US20240391997A1 (en) 2021-07-16 2024-11-28 Brightpath Biotherapeutics Co., Ltd. Anti-tim-3 antigen antibody or antibody derivative, and use thereof
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
CN118043352A (zh) 2021-09-02 2024-05-14 德国癌症研究中心公共法律基金会 副作用减少的抗cecam6抗体
WO2023078900A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023118165A1 (en) 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
IL317319A (en) 2022-06-02 2025-01-01 Bristol Myers Squibb Co Antibody compounds and methods of using them
US20250381272A1 (en) 2022-06-22 2025-12-18 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
JP2025525937A (ja) 2022-08-05 2025-08-07 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
EP4568670A1 (en) 2022-08-10 2025-06-18 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
EP4587040A1 (en) 2022-09-14 2025-07-23 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
CN120712102A (zh) 2022-12-13 2025-09-26 朱诺治疗学股份有限公司 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024161015A1 (en) 2023-02-03 2024-08-08 Institut National de la Santé et de la Recherche Médicale Method to treat age-related diseases
WO2024200571A1 (en) 2023-03-28 2024-10-03 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
WO2024231384A1 (en) 2023-05-10 2024-11-14 Institut National de la Santé et de la Recherche Médicale Compositions for treating senescence related disease
WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
CN116444673B (zh) * 2023-06-14 2023-09-15 北京汇智和源生物技术有限公司 人源膜cd14单克隆抗体及其制备方法和应用
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025068180A1 (en) 2023-09-25 2025-04-03 Institut National de la Santé et de la Recherche Médicale Methods of treatment of cancer by targetting cancer - associated fibroblasts
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
CN117257977A (zh) * 2023-11-07 2023-12-22 正大天晴药业集团南京顺欣制药有限公司 用于制备抗体药物偶联物的方法
WO2025111989A1 (zh) * 2023-11-30 2025-06-05 华东师范大学 嵌合抗原受体及其应用
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
WO2025132770A1 (en) 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Affitins for the treatment of cancer
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025166550A1 (zh) * 2024-02-06 2025-08-14 香港北恒生物科技有限公司 工程化细胞及其用途
WO2025210123A1 (en) 2024-04-03 2025-10-09 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating cancers
WO2025219330A1 (en) 2024-04-15 2025-10-23 Institut National de la Santé et de la Recherche Médicale Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
WO2025228998A1 (en) 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma
WO2025247829A1 (en) 2024-05-27 2025-12-04 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating prostate cancer
WO2026013071A1 (en) 2024-07-09 2026-01-15 Institut National de la Santé et de la Recherche Médicale Setdb1 inhibitor for use in the treatment of uveal melanoma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417984A1 (en) * 2009-04-10 2012-02-15 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
CN103079644A (zh) * 2010-06-11 2013-05-01 协和发酵麒麟株式会社 抗tim-3抗体

Family Cites Families (456)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
DE3381783D1 (de) 1982-03-03 1990-09-13 Genentech Inc Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
AU1807188A (en) 1987-04-10 1988-11-04 Xoma Corporation Human monoclonal antibodies binding determinants of gram negative bacteria
JPH021556A (ja) 1988-06-09 1990-01-05 Snow Brand Milk Prod Co Ltd ハイブリッド抗体及びその作製方法
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
ES2315612T3 (es) 1991-04-10 2009-04-01 The Scripps Research Institute Genotecas de receptores heterodimericos usando fagemidos.
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US6511663B1 (en) 1991-06-11 2003-01-28 Celltech R&D Limited Tri- and tetra-valent monospecific antigen-binding proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
JP3722375B2 (ja) 1991-06-27 2005-11-30 ブリストル−マイヤーズ スクイブ カンパニー Ｃｔｌａ４レセプター、それを含有する融合タンパク質およびそれらの使用
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DK0654085T3 (da) 1992-01-23 1997-09-22 Merck Patent Gmbh Monomere og dimere antistof-fragment-fusionsproteiner
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
AU675223B2 (en) 1992-05-08 1997-01-30 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
DK1238986T3 (da) 1992-10-28 2008-09-29 Genentech Inc Anvendelse af antagonister mod vaskulær endotelcellevækstfaktor
GB9323648D0 (en) 1992-11-23 1994-01-05 Zeneca Ltd Proteins
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
IL108501A (en) 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
WO1996013583A2 (en) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1997007671A1 (en) 1995-08-29 1997-03-06 Kirin Beer Kabushiki Kaisha Chimeric animal and method for constructing the same
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
AU6873396A (en) 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
WO1997038102A1 (en) 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
JP4440344B2 (ja) 1996-08-16 2010-03-24 シェーリング コーポレイション 哺乳動物細胞表面抗原；関連試薬
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
TR199902818T2 (xx) 1997-04-07 2000-05-22 Genentech, Inc. Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
DE69836729T2 (de) 1997-04-07 2007-12-13 Genentech, Inc., South San Francisco Anti-vefg antibodies
CA2288992C (en) 1997-04-30 2012-06-12 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
CA2304254C (en) 1997-06-11 2012-05-22 Hans Christian Thogersen Trimerising module
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CA2308114A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
ATE461282T1 (de) 1997-10-27 2010-04-15 Bac Ip Bv Multivalente antigenbindende proteine
CA2317727C (en) 1998-01-23 2013-01-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Multipurpose antibody derivatives
IL137409A0 (en) 1998-02-09 2001-07-24 Genentech Inc Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
DE69925909T2 (de) 1998-04-15 2006-05-11 Brigham & Women's Hospital, Inc., Boston T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
ES2207278T3 (es) 1998-07-28 2004-05-16 Micromet Ag Heterominicuerpos.
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
PT1137436E (pt) 1998-12-03 2008-09-15 Univ California Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
FR2794025A1 (fr) 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
WO2000073498A1 (en) 1999-06-02 2000-12-07 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
EP1196186B1 (en) 1999-07-12 2007-10-31 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
AU784062B2 (en) 1999-08-23 2006-01-19 Dana-Farber Cancer Institute, Inc. Novel B7-4 molecules and uses therefor
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1292619B1 (en) 2000-06-06 2008-02-06 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
JP2004501624A (ja) 2000-06-28 2004-01-22 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
CN1461344A (zh) 2000-07-25 2003-12-10 免疫医疗公司 多价靶结合蛋白
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ES2372522T3 (es) 2000-09-20 2012-01-23 Amgen Inc. Moléculas de tipo b7 y usos de las mismas.
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
JP2004511503A (ja) 2000-10-20 2004-04-15 大野　典也 疾患を治療するための融合細胞およびサイトカイン組成物
CN1308447C (zh) 2000-10-20 2007-04-04 中外制药株式会社 低分子化的激动剂抗体
WO2002039813A1 (en) 2000-11-15 2002-05-23 Ono Pharmaceutical Co., Ltd. Pd-1-lacking mouse and use thereof
JP2002194491A (ja) 2000-12-27 2002-07-10 Daido Steel Co Ltd ばね用鋼材
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002072635A2 (en) 2001-03-13 2002-09-19 University College London Specific binding members
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
MXPA03008959A (es) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, un receptor para b7-4 y sus usos.
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
US6727072B2 (en) 2001-05-01 2004-04-27 Dako Corporation EGF-r detection kit
US6592849B2 (en) 2001-06-21 2003-07-15 Colgate Palmolive Company Chewing gum to control malodorous breath
ATE477280T1 (de) 2001-06-28 2010-08-15 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
JP4572276B2 (ja) 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
JP2003029846A (ja) 2001-07-11 2003-01-31 Sanyo Electric Co Ltd 流量調整器および流量調整器を備えた飲料供給装置
ATE524495T1 (de) 2001-07-31 2011-09-15 Ono Pharmaceutical Co Pd-1-spezifische substanz
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
ES2269793T3 (es) 2001-10-30 2007-04-01 Novartis Ag Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2003049684A2 (en) 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
CN100522967C (zh) 2002-02-01 2009-08-05 阿里亚德基因治疗公司 含磷化合物及其应用
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
PL230179B1 (pl) 2002-03-13 2018-09-28 Array Biopharma Inc N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych
US8030461B2 (en) 2002-04-15 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for constructing scDb libraries
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
DK1572106T3 (da) 2002-11-15 2010-08-23 Novartis Vaccines & Diagnostic Fremgangsmåde til forebyggelse og behandling af cancermetastase og knogletab forbundet med cancermetastase
US7449300B2 (en) 2002-11-21 2008-11-11 Mayo Foundation For Medical Education And Research Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
AU2004210779B2 (en) 2003-02-11 2010-06-10 Cancer Research Technology Ltd Isoxazole compounds as inhibitors of heat shock proteins
PT1897548E (pt) 2003-02-28 2013-11-19 Univ Johns Hopkins Regulação de células t
GB0305702D0 (en) 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
JP2006526408A (ja) 2003-04-22 2006-11-24 アイビーシー、ファーマシューティカルズ 多価タンパク質複合体
KR20060052681A (ko) 2003-05-23 2006-05-19 와이어쓰 Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도
EP1629010A1 (en) 2003-05-30 2006-03-01 Genentech, Inc. Treatment with anti-vegf antibodies
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
EP1638510B1 (en) 2003-07-01 2015-09-02 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CN1902227A (zh) 2003-10-03 2007-01-24 布赖汉姆妇女医院 Tim－3配体及其方法
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
EP1682103A1 (en) 2003-10-27 2006-07-26 Novartis AG Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
EP1692318A4 (en) 2003-12-02 2008-04-02 Genzyme Corp COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
WO2005062916A2 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
US8383575B2 (en) 2004-01-30 2013-02-26 Paul Scherrer Institut (DI)barnase-barstar complexes
US20050276756A1 (en) 2004-03-24 2005-12-15 Hoo William S Compositions as adjuvants to improve immune responses to vaccines and methods of use
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
CN102229609A (zh) 2004-05-13 2011-11-02 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
RS50569B (sr) 2004-06-11 2010-05-07 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
EP1768999B1 (en) 2004-06-30 2013-06-19 Mayo Foundation For Medical Education And Research sHIgM12 antibody useful to treat multiple sclerosis
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
US20090123413A1 (en) 2004-08-23 2009-05-14 Britta Hardy Use of bat monoclonal antibody for immunotherapy
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
ES2671893T3 (es) 2004-10-06 2018-06-11 Mayo Foundation For Medical Education And Research B7-H1 y PD-1 en el tratamiento del carcinoma de células renales
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CN101484182B (zh) 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
US8652465B2 (en) 2005-06-08 2014-02-18 Emory University Methods and compositions for the treatment of persistent infections
AU2006261127B2 (en) 2005-06-17 2012-03-15 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
WO2007004415A1 (ja) 2005-07-01 2007-01-11 Murata Manufacturing Co., Ltd. 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
DK1912671T3 (da) 2005-07-18 2017-11-27 Seattle Genetics Inc Beta-glucuronid-linker-lægemiddelkonjugater
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1757622B1 (en) 2005-08-26 2009-12-23 PLS Design GmbH Bivalent IgY antibody constructs for diagnostic and therapeutic applications
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
WO2007062466A1 (en) 2005-11-29 2007-06-07 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
SI1966202T1 (sl) 2005-12-13 2012-01-31 Incyte Corp S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
WO2007082154A2 (en) 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008010561A (es) 2006-02-15 2009-03-02 Imclone Systems Inc Anticuerpos funcionales.
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
WO2007112362A2 (en) 2006-03-24 2007-10-04 The Regents Of The University Of California Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
US8501185B2 (en) 2006-05-25 2013-08-06 Bayer Healthcare Llc Dimeric molecular complexes
US20070274985A1 (en) 2006-05-26 2007-11-29 Stefan Dubel Antibody
EP3805269A1 (en) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Single-chain multivalent binding proteins with effector function
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
AR064801A1 (es) 2006-08-18 2009-04-29 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
US7741446B2 (en) 2006-08-18 2010-06-22 Armagen Technologies, Inc. Fusion antibodies that cross the blood-brain barrier in both directions
MX2009001878A (es) 2006-08-21 2009-03-03 Genentech Inc Compuestos de aza-benzofuranilo y metodos de uso.
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
CA2663521A1 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorial therapy of cancer and infectious diseases with anti-b7-h1 antibodies
CN101965363A (zh) 2006-11-02 2011-02-02 丹尼尔·J·卡鹏 具有活动部分的杂合免疫球蛋白
EP2081961A2 (en) 2006-11-15 2009-07-29 The Brigham and Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
KR101532256B1 (ko) 2006-11-22 2015-06-29 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
CN103641816A (zh) 2006-12-08 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN101616895A (zh) 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
HUE030139T2 (en) 2006-12-27 2017-04-28 Univ Emory Compositions and methods for the treatment of infections
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
WO2009029342A2 (en) 2007-07-13 2009-03-05 The Johns Hopkins University B7-dc variants
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
US9243052B2 (en) 2007-08-17 2016-01-26 Daniel Olive Method for treating and diagnosing hematologic malignancies
AU2007358569B2 (en) 2007-09-07 2014-09-04 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
KR20100097716A (ko) 2007-11-27 2010-09-03 아블린쓰 엔.브이. 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
GB2468232B (en) 2007-11-30 2012-10-24 Glaxo Group Ltd Antigen-bindng constructs
CL2008003810A1 (es) 2007-12-19 2009-05-22 Genentech Inc Compuestos derivados de 5-anilino imidazol[1,5-a]piridina o pirazina, inhibidores de la actividad mek quinasa; composiciones farmaceuticas que los contienen; y su uso para tratar trastornos hiperproliferativos y una enfermedad inflamatoria.
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
WO2009091547A1 (en) 2008-01-15 2009-07-23 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
US20110059106A1 (en) 2008-01-29 2011-03-10 Brigham And Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
WO2009120903A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
TWI472529B (zh) 2008-05-21 2015-02-11 Incyte Corp ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
GEP20125502B (en) 2008-05-23 2012-04-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
KR20110044992A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
JP5945096B2 (ja) 2008-07-04 2016-07-05 小野薬品工業株式会社 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
EP3009436B1 (en) 2008-07-08 2019-06-05 Intellikine, LLC Kinase inhibitors and methods of use
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
SI2331547T1 (sl) 2008-08-22 2014-11-28 Novartis Ag Pirolopirimidinske spojine kot CDK inhibitorji
MX2011002250A (es) 2008-08-25 2011-08-17 Amplimmune Inc Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
HUE027525T2 (en) 2008-08-25 2016-11-28 Amplimmune Inc PD-1 Antagonist preparations and their use
BRPI0918268B1 (pt) 2008-09-02 2021-08-03 Novartis Ag Derivados de picolinamida, seu uso, e composição farmacêutica
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN102149820B (zh) 2008-09-12 2014-07-23 国立大学法人三重大学 能够表达外源gitr配体的细胞
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
JP2012501670A (ja) 2008-09-12 2012-01-26 アイシス・イノベーション・リミテッド Ｐｄ−１特異抗体およびその使用
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
MX2011004467A (es) 2008-10-31 2011-07-28 Biogen Idec Inc Moleculas de objetivo light y usos de las mismas.
WO2010056735A1 (en) 2008-11-11 2010-05-20 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
KR101749353B1 (ko) 2008-11-28 2017-06-20 노파르티스 아게 Ｈｓｐ90 억제제 및 ｍｔｏｒ 억제제를 포함하는 제약 조합물
US9598491B2 (en) 2008-11-28 2017-03-21 Emory University Methods for the treatment of infections and tumors
CA2745271A1 (en) 2008-12-04 2010-06-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
PT2376535T (pt) 2008-12-09 2017-06-23 Hoffmann La Roche Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
WO2010084999A1 (en) 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
SG10201402960SA (en) 2009-03-05 2014-08-28 Abbvie Inc IL-17 Binding Proteins
WO2010102278A1 (en) 2009-03-06 2010-09-10 President And Fellows Of Harvard College Methods and compositions for the generation and maintenance of regulatory t cells
WO2010110346A1 (ja) 2009-03-24 2010-09-30 独立行政法人理化学研究所 白血病幹細胞マーカー
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US8598322B2 (en) 2009-04-30 2013-12-03 Tel Hashomer Medical Research Infrastucture and Services Ltd. Anti CEACAM1 antibodies and methods of using same
WO2010127294A2 (en) 2009-05-01 2010-11-04 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
EP2425010A4 (en) 2009-05-01 2013-10-23 Abbvie Inc IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
CN102802661B (zh) 2009-06-22 2016-01-13 米迪缪尼有限公司 用于位点特异性偶联的工程改造的Fc区
RS53384B (sr) 2009-06-26 2014-10-31 Novartis Ag Derivati 1,3-disupstituisanog imidazolidin-2-on kao inhibitori cyp 17
EP3659596A1 (en) 2009-07-20 2020-06-03 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with paclitaxel for the synergistic treatment of proliferative diseases
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
HUE049825T2 (hu) 2009-09-03 2020-10-28 Merck Sharp & Dohme Anti-GITR antitestek
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
NZ701769A (en) 2009-09-16 2016-06-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
WO2011041613A2 (en) 2009-09-30 2011-04-07 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
CN107337734A (zh) 2009-12-04 2017-11-10 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JP5851419B2 (ja) 2009-12-29 2016-02-03 エマージェント プロダクト デベロップメント シアトル， エルエルシー ヘテロダイマー結合タンパク質およびその使用
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011117057A1 (de) * 2010-03-22 2011-09-29 Leibniz-Institut für Plasmaforschung und Technologie e.V. Aktive thermosonde
EP4477668A3 (en) 2010-04-20 2025-03-19 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
DK2571532T3 (en) 2010-05-14 2017-08-28 Abbvie Inc IL-1 BINDING PROTEINS
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012018538A2 (en) 2010-07-26 2012-02-09 Schering Corporation Bioassays for determining pd-1 modulation
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
PT2606070T (pt) 2010-08-20 2017-03-31 Novartis Ag Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
EP2608803A4 (en) 2010-08-26 2014-01-15 Abbvie Inc IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US20120258108A1 (en) 2010-11-02 2012-10-11 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US20120263722A1 (en) 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2638066A4 (en) 2010-11-09 2015-06-03 Medimmune Llc ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US8814630B2 (en) 2011-01-04 2014-08-26 Carl T. Rittberger PVC beehive
CA2825064C (en) 2011-02-04 2022-08-30 Genentech, Inc. Fc variants and methods for their production
KR102031020B1 (ko) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US20140234320A1 (en) 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
CN103796680A (zh) 2011-06-21 2014-05-14 约翰霍普金斯大学 用于增强针对赘生物的基于免疫的治疗的聚焦放射
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
CA2849259A1 (en) 2011-09-19 2013-03-28 The Johns Hopkins University Cancer immunotherapy
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013060867A2 (en) 2011-10-27 2013-05-02 Genmab A/S Production of heterodimeric proteins
CN104011076A (zh) 2011-10-31 2014-08-27 默沙东公司 用于制备具有改善性能的抗体的方法
CA2856895C (en) 2011-11-28 2021-10-26 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
US9556271B2 (en) 2011-12-01 2017-01-31 The Brigham And Women's Hospital, Inc. Anti-CEACAM1 recombinant antibodies for cancer therapy
CN102492038B (zh) * 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
EP2861579B9 (en) 2012-05-15 2018-08-29 Novartis AG Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CA3213528A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9315489B2 (en) 2012-05-15 2016-04-19 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
CN104379574B (zh) 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
US9340537B2 (en) 2012-05-15 2016-05-17 Novatis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
MY186099A (en) 2012-05-31 2021-06-22 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
EP2854843A4 (en) 2012-05-31 2016-06-01 Sorrento Therapeutics Inc ANTIGEN-BINDING PROTEINS FOR BINDING PD-L1
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CA2880198A1 (en) 2012-07-27 2014-01-30 Novartis Ag Prediction of treatment response to jak/stat inhibitor
US20150190505A1 (en) 2012-07-30 2015-07-09 Alex Wah Hin Yeung Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator
EP2879709B1 (en) 2012-07-31 2020-01-08 The Brigham and Women's Hospital, Inc. Modulation of the immune response
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
TWI472974B (zh) 2012-09-06 2015-02-11 Au Optronics Corp 多類物體觸控點偵測方法
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
HUE035503T2 (en) 2012-10-02 2018-05-02 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
CN114507282B (zh) 2012-10-04 2025-05-16 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
EP3679950A1 (en) 2012-10-12 2020-07-15 The Brigham and Women's Hospital, Inc. Enhancement of the immune response
BR112015010477A2 (pt) 2012-11-08 2017-07-11 Novartis Ag combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
CA2891938A1 (en) 2012-11-28 2014-06-05 Novartis Ag Combination therapy
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
PT2996473T (pt) 2013-05-18 2019-11-18 Univ California Composições e métodos para a ativação da sinalização dependente do ''estimulador de genes de interferão''
CN103242448B (zh) 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
SG11201509742QA (en) 2013-06-03 2015-12-30 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
BR112016000853A2 (pt) 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
KR102232153B1 (ko) 2013-08-20 2021-03-24 머크 샤프 앤드 돔 코포레이션 Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
IL321966A (en) 2013-09-11 2025-09-01 Medimmune Ltd Anti-B7-H1 antibodies for tumor treatment
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CA3078121A1 (en) 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
EP3508502B1 (en) 2013-09-20 2023-04-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP3626742A1 (en) 2013-09-27 2020-03-25 F. Hoffmann-La Roche AG Anti-pdl1 antibody formulations
US10202454B2 (en) 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
US20160303231A1 (en) 2013-12-11 2016-10-20 Robert Iannone Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
EP3083687A2 (en) 2013-12-17 2016-10-26 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
BR112016014410A2 (pt) 2013-12-20 2018-02-20 The Broad Institute Inc. terapia de combinação com vacina de neoantígeno
WO2015103602A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
SI3094351T1 (sl) 2014-01-15 2022-05-31 Kadmon Corporation, Llc Imunomodulatorna sredstva
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015214404B2 (en) 2014-02-04 2020-10-01 Incyte Corporation Combination of a PD-1 antagonist and an IDO1 inhibitor for treating cancer
CN105979961B (zh) 2014-02-05 2020-12-18 西达-赛奈医疗中心 用于治疗癌症和感染性疾病的方法和组合物
DK3889172T3 (da) 2014-02-10 2024-06-17 Merck Patent Gmbh Målrettet TGF-Beta-inhibering
US20150259420A1 (en) * 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CA2947932C (en) 2014-05-29 2021-03-30 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
PL3183268T3 (pl) * 2014-08-19 2020-09-07 Novartis Ag Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US20170281624A1 (en) 2014-09-13 2017-10-05 Novartis Ag Combination therapies of alk inhibitors
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
EP3212670B1 (en) 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
US20170320954A1 (en) 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
EP3328407A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination of pd-1 antagonist with an egfr inhibitor
EP3878465A1 (en) * 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
JP6878405B2 (ja) * 2015-07-29 2021-05-26 ノバルティス アーゲー Ｐｄ−１に対する抗体分子を含む組み合わせ治療
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
JP6840127B2 (ja) 2015-07-29 2021-03-10 ノバルティス アーゲー がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
WO2017025918A1 (en) 2015-08-11 2017-02-16 Novartis Ag 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
UA123270C2 (uk) 2015-12-07 2021-03-10 Мерк Патент Гмбх Водний фармацевтичний препарат, який містить антитіло до pd-l1 авелумаб
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
EP3448428A4 (en) 2016-04-25 2019-11-27 Medimmune, LLC COMPOSITIONS WITH CO FORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES
AU2018292618A1 (en) 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof
KR20200031659A (ko) 2017-07-20 2020-03-24 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
WO2019018640A1 (en) 2017-07-21 2019-01-24 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417984A1 (en) * 2009-04-10 2012-02-15 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
CN103079644A (zh) * 2010-06-11 2013-05-01 协和发酵麒麟株式会社 抗tim-3抗体

Also Published As

Publication number Publication date
CL2016001716A1 (es) 2017-06-09
CU24427B1 (es) 2019-06-04
EA201691556A1 (ru) 2016-12-30
HUE045065T2 (hu) 2019-12-30
US20200308277A1 (en) 2020-10-01
BR112016016436A2 (pt) 2017-12-12
JP6856694B2 (ja) 2021-04-07
US10472419B2 (en) 2019-11-12
TWI769434B (zh) 2022-07-01
SG11201605627TA (en) 2016-08-30
MY187296A (en) 2021-09-20
IL246693A0 (en) 2016-08-31
PE20170330A1 (es) 2017-04-21
KR20160113272A (ko) 2016-09-28
ES2972425T3 (es) 2024-06-12
ME03489B (me) 2020-01-20
HRP20191083T1 (hr) 2019-09-20
AU2020227017A1 (en) 2020-09-17
JP2021104025A (ja) 2021-07-26
AU2020227017B2 (en) 2022-09-15
EP3560959A1 (en) 2019-10-30
EP4324518A3 (en) 2024-05-22
KR102366218B1 (ko) 2022-02-23
US20200223917A1 (en) 2020-07-16
CA2936863A1 (en) 2015-08-06
RS59065B1 (sr) 2019-09-30
AU2015210750A1 (en) 2016-07-21
EP3560959B1 (en) 2023-11-22
TW202043286A (zh) 2020-12-01
CR20160347A (es) 2017-03-10
JO3567B1 (ar) 2020-07-05
IL246693B (en) 2022-11-01
CN113896791A (zh) 2022-01-07
EP4324518A2 (en) 2024-02-21
US20170190777A1 (en) 2017-07-06
MX2016009961A (es) 2017-01-11
US9605070B2 (en) 2017-03-28
JOP20200096A1 (ar) 2017-06-16
PL3099717T3 (pl) 2019-10-31
NZ761188A (en) 2023-06-30
EP3099717A1 (en) 2016-12-07
SI3099717T1 (sl) 2019-09-30
US20150218274A1 (en) 2015-08-06
WO2015117002A1 (en) 2015-08-06
UY35973A (es) 2015-08-31
US10981990B2 (en) 2021-04-20
CN106132991B (zh) 2021-07-02
US9884913B2 (en) 2018-02-06
US20220185883A1 (en) 2022-06-16
US11155620B2 (en) 2021-10-26
MX375953B (es) 2025-03-07
KR20220028145A (ko) 2022-03-08
PH12016501482A1 (en) 2016-08-22
CY1121893T1 (el) 2020-10-14
EP3099717B1 (en) 2019-03-27
LT3099717T (lt) 2019-09-10
JP2019147809A (ja) 2019-09-05
UY40476A (es) 2023-11-15
MX2020002694A (es) 2020-07-28
IL246693B2 (en) 2023-03-01
NZ722042A (en) 2023-06-30
ES2732901T3 (es) 2019-11-26
PT3099717T (pt) 2019-07-10
PH12016501482B1 (en) 2024-02-16
DK3099717T3 (da) 2019-07-01
US20170198041A1 (en) 2017-07-13
AU2015210750B2 (en) 2020-08-20
JP2017511687A (ja) 2017-04-27
CN106132991A (zh) 2016-11-16
TW201612193A (en) 2016-04-01
ECSP16070447A (es) 2019-07-31
CU20160118A7 (es) 2017-02-02
JP6539667B2 (ja) 2019-07-03

Similar Documents

Publication Publication Date Title
TWI686406B (zh) 結合ｔｉｍ-３之抗體分子及其用途
JP6518370B2 (ja) Ｐｄ−１に対する抗体分子およびその使用
JP2024063093A (ja) Ｌａｇ－３に対する抗体分子およびその使用
HK40008387A (en) Antibody molecules to tim-3 and uses thereof
HK40108446A (en) Antibody molecules to tim-3 and uses thereof
BR112016016436B1 (pt) Molécula de anticorpo isolada bem como método in vitro para sua produção e uso da mesma, composição farmacêutica, ácidos nucleicos isolados, vetor de expressão e método in vitro ou ex vivo para detecção de tim-3 em uma amostra biológica
HK1229354B (en) Antibody molecules to tim-3 and uses thereof
HK1229354A1 (en) Antibody molecules to tim-3 and uses thereof
EA040365B1 (ru) Молекулы антител к tim-3 и их применение
BR122024022644A2 (pt) Molécula de anticorpo isolada bem como método para produção e uso da mesma, composição farmacêutica, ácidos nucleicos isolados, vetor de expressão, e método in vitro para detecção de tim-3 em uma amostra biológica

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees